These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1995761)

  • 1. Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057.
    Miles S; Levine A; Feldstein M; Carden J; Cabriallas S; Marcus S; Mitsuyasu R; Gill P
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):17-23. PubMed ID: 9557213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of interferon-alpha2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi's sarcoma. Swiss HIV Cohort Study.
    Opravil M; Hirschel B; Bucher HC; Lüthy R
    Int J STD AIDS; 1999 Jun; 10(6):369-75. PubMed ID: 10414879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with ZDV and interferon-alpha-2a promotes tumor regression.
    J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study.
    Shepherd FA; Beaulieu R; Gelmon K; Thuot CA; Sawka C; Read S; Singer J
    J Clin Oncol; 1998 May; 16(5):1736-42. PubMed ID: 9586886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study.
    Krown SE; Li P; Von Roenn JH; Paredes J; Huang J; Testa MA
    J Interferon Cytokine Res; 2002 Mar; 22(3):295-303. PubMed ID: 12034036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
    Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
    Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma.
    Krown SE
    J Interferon Cytokine Res; 1998 Apr; 18(4):209-14. PubMed ID: 9568721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classic Kaposi's sarcoma: low-dose interferon alfa treatment.
    Tur E; Brenner S
    Dermatology; 1998; 197(1):37-42. PubMed ID: 9693183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-human immunodeficiency virus Kaposi's sarcoma can be effectively treated with low-dose interferon-alpha despite the persistence of herpesvirus-8.
    Deichmann M; Thome M; Jäckel A; Utermann S; Bock M; Waldmann V; Näher H
    Br J Dermatol; 1998 Dec; 139(6):1052-4. PubMed ID: 9990371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Haemolytic uremic syndrome and acute mesenteric ischemia caused by interferon-alpha-2b in the treatment of Kaposi's sarcoma in an AIDS patient].
    Zaraa I; Maubec E; Valeyrie-Allanore L; Essig M; Charachon A; Chosidow D; Debray MP; Marinho E; Picard-Dahan C; Descamps V; Crickx B
    Ann Dermatol Venereol; 2007 Jan; 134(1):65-7. PubMed ID: 17384548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. Kaposi's Sarcoma ANRS Study Group. Agence Nationale de Recherches sur le SIDA.
    Saiag P; Pavlovic M; Clerici T; Feauveau V; Nicolas JC; Emile D; Chastang C
    AIDS; 1998 Nov; 12(16):2169-76. PubMed ID: 9833858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
    Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C
    J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A report of two non-AIDS associated Kaposi's sarcoma in Malaysia.
    Choon SE; Khoo JJ
    Med J Malaysia; 1997 Dec; 52(4):437-40. PubMed ID: 10968124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous ulcers due to interferon seem not to be related to the dosage.
    Virgili A; Corazza M; Lombardi AR; Sighinolfi L
    J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):141-3. PubMed ID: 10568497
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals.
    Rivero J; Fraga M; Cancio I; Cuervo J; López-Saura P
    Biotherapy; 1997; 10(2):107-13. PubMed ID: 9373732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I interferon: understanding its role in HIV pathogenesis and therapy.
    Bosinger SE; Utay NS
    Curr HIV/AIDS Rep; 2015 Mar; 12(1):41-53. PubMed ID: 25662992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.
    Notermans DW; van Leeuwen R; Lange JM
    Drug Saf; 1996 Sep; 15(3):176-87. PubMed ID: 8879972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Wilde MI; Langtry HD
    Drugs; 1993 Sep; 46(3):515-578. PubMed ID: 7693435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma.
    de Wit R; Danner SA; Bakker PJ; Lange JM; Eeftinck Schattenkerk JK; Veenhof CH
    J Intern Med; 1991 Jan; 229(1):35-40. PubMed ID: 1995761
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.